Aasander Frostner 2022 Abstract Bioblast: Difference between revisions
Tindle Lisa (talk | contribs) (Created page with "{{Abstract |title=left|100px|Åsander Frostner Eleonor <u>Åsander Frostner Eleonor</u>, Simón Serrano S, Chamkha I, Donnelly E, Elmér E, Han...") |
No edit summary |
||
Line 1: | Line 1: | ||
[[File:Bioblast2022 banner.jpg|link=Bioblast_2022]] | |||
{{Abstract | {{Abstract | ||
|title=[[File:Eleonor A Frostner.jpg|left|100px|Åsander Frostner Eleonor]] <u>Åsander Frostner Eleonor</u>, Simón Serrano S, Chamkha I, Donnelly E, Elmér E, Hansson MJ (2022) Towards a treatment for mitochondrial disease: current compounds in clinical development. Bioblast 2022: BEC Inaugural Conference. <br>[[Aasander Frostner 2022 MitoFit|»''MitoFit Preprint''«]] | |title=[[File:Eleonor A Frostner.jpg|left|100px|Åsander Frostner Eleonor]] <u>Åsander Frostner Eleonor</u>, Simón Serrano S, Chamkha I, Donnelly E, Elmér E, Hansson MJ (2022) Towards a treatment for mitochondrial disease: current compounds in clinical development. Bioblast 2022: BEC Inaugural Conference. <br>[[Aasander Frostner 2022 MitoFit|»''MitoFit Preprint''«]] | ||
Line 13: | Line 14: | ||
In this short review, we present the current landscape of mitochondrial disease drug development, focusing on small molecules in clinical trials conducted by industrial sponsor. | In this short review, we present the current landscape of mitochondrial disease drug development, focusing on small molecules in clinical trials conducted by industrial sponsor. | ||
|keywords=mitochondrial disease, clinical development, mechanism of action, small molecules, industrial sponsors | |keywords=mitochondrial disease, clinical development, mechanism of action, small molecules, industrial sponsors | ||
|mipnetlab=SE Lund Elmer E | |mipnetlab=SE Lund Elmer E | ||
}} | }} | ||
== Affiliations == | == Affiliations == | ||
:::: Åsander Frostner E | :::: Åsander Frostner E<sup>1,2</sup>, Simón Serrano S<sup>1,2</sup>, Chamkha I<sup>1,2</sup>, Donnelly E<sup>1</sup>, Elmér E<sup>1,2</sup>, Hansson MJ<sup>1,2</sup> | ||
::::# Abliva AB, Medicon Village, 223 81 Lund, Sweden | |||
::::# Mitochondrial Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden | |||
== Help == | == Help == | ||
* [[MitoPedia: Terms and abbreviations]] | * [[MitoPedia: Terms and abbreviations]] | ||
{{Labeling | {{Labeling | ||
|area=mt-Medicine, Pharmacology;toxicology | |area=mt-Medicine, Pharmacology;toxicology |
Revision as of 13:50, 22 May 2022
Åsander Frostner Eleonor, Simón Serrano S, Chamkha I, Donnelly E, Elmér E, Hansson MJ (2022) Towards a treatment for mitochondrial disease: current compounds in clinical development. Bioblast 2022: BEC Inaugural Conference. »MitoFit Preprint« |
Link: Bioblast 2022: BEC Inaugural Conference
Aasander Frostner Eleonor, Simon Serrano Sonia, Chamkha Imen, Donnelly Ellen, Elmer Eskil, Hansson Magnus J (2022)
Event: Bioblast 2022
Primary mitochondrial diseases are a heterogeneous group of rare genetic disorders affecting approximately 125 persons per million. Mutations underlying these diseases give rise to biological changes (including decrease in energy production and increase in reactive oxygen species), leading to organ failure, and commonly early morbidity. Mitochondrial diseases often present in early childhood and lead to the development of severe symptoms, with severe fatigue and myopathy being some of the most prevalent and debilitating ones.
There is currently no cure for primary mitochondrial diseases, nor any approved pharmaceutical treatments for multisystemic disorders.
Present drug development in mitochondrial diseases focuses mainly on modulation of oxidative stress, regulation of the expression of genes involved in metabolic pathways, modulation of coenzymes, induction of mitochondrial biogenesis, and energy replacement.
In this short review, we present the current landscape of mitochondrial disease drug development, focusing on small molecules in clinical trials conducted by industrial sponsor.
• Keywords: mitochondrial disease, clinical development, mechanism of action, small molecules, industrial sponsors
• O2k-Network Lab: SE Lund Elmer E
Affiliations
- Åsander Frostner E1,2, Simón Serrano S1,2, Chamkha I1,2, Donnelly E1, Elmér E1,2, Hansson MJ1,2
- Abliva AB, Medicon Village, 223 81 Lund, Sweden
- Mitochondrial Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Help
Labels: MiParea: mt-Medicine, Pharmacology;toxicology
Pathology: Inherited
Stress:Mitochondrial disease
Organism: Human